Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 257 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment-Refractory Depression Clear all
Completed Phase 2 Interventional

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

NCT05774665
View directory record Official record
Conditions
Treatment Resistant Depression, Inflammation, Overweight
Interventions
Omega 3, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional Results available

Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

NCT02660528
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

rTMS in Treatment Resistant Depression

NCT02080507
View directory record Official record
Conditions
Depression
Interventions
Active Neuronetics rTMS stimulator, Inactive Neuronetics rTMS stimulator
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Not applicable Interventional

Fermented Milk Product With Probiotic and Its Impact on Mood of Patients With Treatment Resistant Depression

NCT03317678
View directory record Official record
Conditions
Depression
Interventions
BioKefir, Non-fermented milk
Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Jun 10, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional Results available

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

NCT01913535
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
CERC-501, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Results available

A Study of Infliximab for Treatment Resistant Major Depression

NCT00463580
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

NCT01654796
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Low Field Magnetic Stimulation (LFMS), Sham LFMS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jun 10, 2026, 3:27 AM EDT
Withdrawn Not applicable Interventional

An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression

NCT01438242
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chalfont, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jun 10, 2026, 3:27 AM EDT
Terminated No phase listed Observational Results available

Pharmacogenomics for Antidepressant Guidance and Education

NCT01555021
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Genotyping assays
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Jun 10, 2026, 3:27 AM EDT
Active, not recruiting Not applicable Interventional

Compressed Intermittent Theta Burst Stimulation

NCT04684706
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
intermittent Theta Burst Stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jun 10, 2026, 3:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

NCT04239963
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jun 10, 2026, 3:27 AM EDT
Active, not recruiting Early Phase 1 Interventional

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

NCT03573349
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression

NCT00837486
View directory record Official record
Conditions
Depression
Interventions
Reclaim™ DBS System
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Charlestown, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 10, 2026, 3:27 AM EDT
Terminated Phase 2 Interventional Results available

Rapid Antidepressant Effects of Leucine

NCT03079297
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
L-Leucine, Maltodextrin
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

NCT05220410
View directory record Official record
Conditions
Treatment Resistant Depression, Suicidal Ideation
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 10, 2026, 3:27 AM EDT
Recruiting No phase listed Observational

Natural History of Depression, Bipolar Disorder and Suicide Risk

NCT06462196
View directory record Official record
Conditions
Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine Nasal Spray
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
51
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Not applicable Interventional Results available

Treatment Resistant Depression (Pilot)

NCT01179009
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Ketamine, Clonidine, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jun 10, 2026, 3:27 AM EDT
Terminated Phase 3 Interventional Results available

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

NCT03610048
View directory record Official record
Conditions
Refractory Major Depressive Disorder
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 4 Interventional

Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication

NCT00375843
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Sertraline
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Ketamine Plus Lithium in Treatment-Resistant Depression

NCT01880593
View directory record Official record
Conditions
Depression
Interventions
Lithium, Ketamine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Results available

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

NCT00305565
View directory record Official record
Conditions
Depression
Interventions
VNS Therapy
Device
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
26
States / cities
Tucson, Arizona • Sacramento, California • Marietta, Georgia + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Jun 10, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 10, 2026, 3:27 AM EDT